Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis?
- PMID: 15314107
- PMCID: PMC1739214
- DOI: 10.1136/jnnp.2004.046342
Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis?
Comment on
-
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1294-9. doi: 10.1136/jnnp.2004.037259. J Neurol Neurosurg Psychiatry. 2004. PMID: 15314118 Free PMC article. Clinical Trial.
Similar articles
-
Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.Neurology. 2005 Mar 8;64(5):778-9. doi: 10.1212/01.WNL.0000153532.80277.21. Neurology. 2005. PMID: 15753408 No abstract available.
-
Predictive markers for response to interferon therapy in patients with multiple sclerosis.Neurology. 2008 Mar 25;70(13 Pt 2):1119-27. doi: 10.1212/01.wnl.0000304040.29080.7b. Epub 2008 Feb 13. Neurology. 2008. PMID: 18272865
-
NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.Brain. 2015 Mar;138(Pt 3):644-52. doi: 10.1093/brain/awu388. Epub 2015 Jan 12. Brain. 2015. PMID: 25586466 Free PMC article.
-
Use of interferon-beta in the treatment of multiple sclerosis.Adv Neurol. 2006;98:257-71. Adv Neurol. 2006. PMID: 16400838 Review. No abstract available.
-
Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.Exp Neurol. 2007 Jan;203(1):1-4. doi: 10.1016/j.expneurol.2006.09.007. Epub 2006 Oct 25. Exp Neurol. 2007. PMID: 17069803 Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical